Dr. Reddy's can now make and export its Ozempic rival
What's the story
The Delhi High Court has dismissed a plea by Novo Nordisk to stop Dr. Reddy's Laboratories from making and exporting semaglutide. The court upheld its January 2026 ruling after hearing appeals against a single-judge bench order, that had allowed Dr. Reddy's to make and export semaglutide to markets where the drug is not patented.
Market impact
Novo Nordisk to launch Extensior in India soon
The court's decision comes as Novo Nordisk is preparing to launch a new brand of semaglutide, Extensior, in India. Semaglutide is the active pharmaceutical ingredient in Novo's popular drugs Ozempic and Wegovy. The former is used for diabetes treatment while the latter is prescribed for obesity and weight management. In December 2025, a single-judge bench of the Delhi HC ruled that Novo Nordisk had failed to prove its case against Dr. Reddy's exporting this drug ingredient to non-patented markets.
Patent dispute
Impact on generic manufacturers
Novo Nordisk has maintained that its semaglutide patent is valid in India until March 20, 2026. The court's decision is likely to impact generic manufacturers looking to export semaglutide to non-patented markets. Meanwhile, shares of Novo Nordisk were up by some 1.2% during the early hours of trading in the European market.